MiR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor

Journal of Clinical Pathology

Volumn 67, Issue 3, 2014, Pages 198-203

  Pichler, Martin ^a   Winter, Elke ^a   Ress, Anna Lena ^a   Bauernhofer, Thomas ^a   Gerger, Armin ^a   Kiesslich, Tobias ^b   Lax, Sigurd ^c   Samonigg, Hellmut ^a   Hoefler, Gerald ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c General Hospital Graz West   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CANCER RESEARCH; COLORECTAL CANCER;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894255801     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201904     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CANCER 2012; 62:10-29.
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. NEJM 2004;351:337-45. (Pubitemid 38944402)
3. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. JCO 2010;28:4697-705.
4. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. JCO 2010;28:4706-13.
5. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. JCO 2008;26:1626-34.
6. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. NEJM 2008;359:1757-65.
7. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. JCO 2008;26:374-9. (Pubitemid 351171687)
8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66. (Pubitemid 44629897)
9. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. JCO 2004;22:1209-14. (Pubitemid 41079833)
10. Chen CZ, Li L, Lodish HF, et al. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-6. (Pubitemid 38055775)
11. Qin L, Chen Y, Niu Y, et al. A deep investigation into the adipogenesis mechanism: profile of microRNAs regulating adipogenesis by modulating the canonical Wnt/beta-catenin signaling pathway. BMC Genomics 2010;11:320.
12. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, et al. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol 2006;8:278-84. (Pubitemid 43336070)
13. Kazenwadel J, Michael MZ, Harvey NL. Prox1 expression is negatively regulated by miR-181 in endothelial cells. Blood 2010;116:2395-401.
14. Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009;50:472-80.
15. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66:11590-3. (Pubitemid 46094168)
16. Li Z, Huang H, Li Y, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 2012;119:2314-24.
17. Yang CC, Hung PS, Wang PW, et al. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J Oral Pathol Med 2011;40:397-404.
18. Ji J, Yamashita T, Wang XW. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci 2011;1:4.
19. Wu ZQ, Brabletz T, Fearon E, et al. Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. PNAS 2012;109:11312-17.
20. Pichler M, Winter E, Stotz M, et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. BJC 2012;106:1826-32.
21. Weidlich S, Walsh K, Crowther D, et al. Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. BJC 2011;105:246-54.
22. Pichler M, Balic M, Stadelmeyer E, et al. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. JMD 2009;11:140-7.
23. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-8. (Pubitemid 351818697)
24. Atzpodien J, Royston P, Wandert T, et al. Metastatic renal carcinoma comprehensive prognostic system. BJC 2003;88:348-53. (Pubitemid 36308143)
25. Shin KH, Bae SD, Hong HS, et al. miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun 2011;404:896-902.
26. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4:143-59.
27. Ma YY, Tao HQ. Microribonucleic acids and gastric cancer. Cancer Sci 2012;103:620-5.
28. Shi L, Cheng Z, Zhang J, et al. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 2008;1236:185-93.
29. Schulte JH, Marschall T, Martin M, et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 2010;38:5919-28.
30. Wang Y, Yu Y, Tsuyada A, et al. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011;30:1470-80.
31. Chandra SH, Wacker I, Appelt UK, et al. A common role for various human truncated adenomatous polyposis coli isoforms in the control of beta-catenin activity and cell proliferation. PloS one 2012;7:e34479.
32. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. JCO 2010;28:1254-61.
33. Mekenkamp LJ, Tol J, Dijkstra JR, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 2012;12:292.